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The clinical results of the CSAW Trial1,2 
(Can Shoulder Arthroscopy Work?; ISRCTN 
33864128) were recently published. This rand-
omized controlled trial (RCT) aimed to address 
uncertainties about the most appropriate treatment 
for patients with subacromial pain in the shoulder. 
This common condition3 is associated with signif-
icant impairment of quality of life and a substan-
tial socioeconomic burden.4 The trial investigated 
the mechanism by which surgical decompression5 
might benefit patients, and the effectiveness of this 
treatment. The aims were addressed by compar-
ing the clinical and cost-effectiveness of arthro-
scopic subacromial decompression (referred to 
henceforth as decompression), arthroscopy only 
(diagnostic investigative arthroscopy and thus the 
surgery without removal of the tissue and bone 
spur), and no treatment. Crucially, the arthros-
copy only arm was included to investigate the 
mechanisms of decompression by comparing 
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Aims
The aims of this study were to compare the use of resources, costs, and quality of life 
outcomes associated with subacromial decompression, arthroscopy only (placebo surgery), 
and no treatment for subacromial pain in the United Kingdom National Health Service 
(NHS), and to estimate their cost-effectiveness.
Patients and Methods
The use of resources, costs, and quality-adjusted life-years (QALYs) were assessed 
in the trial at six months and one year. Results were extrapolated to two years after 
randomization. Differences between treatment arms, based on the intention-to-treat 
principle, were adjusted for covariates and missing data were handled using multiple 
imputation. Incremental cost-effectiveness ratios were calculated, with uncertainty around 
the values estimated using bootstrapping.
Results
Cumulative mean QALYs/mean costs of health care service use and surgery per patient 
from baseline to 12 months were estimated as 0.640 (standard error (se) 0.024)/£3147  
(se 166) in the decompression arm, 0.656 (se 0.020)/£2830 (se 183) in the arthroscopy only 
arm and 0.522 (se 0.029)/£1451 (se 151) in the no treatment arm. Statistically significant 
differences in cumulative QALYs and costs were found at six and 12 months for the 
decompression versus no treatment comparison only. The probabilities of decompression 
being cost-effective compared with no treatment at a willingness-to-pay threshold of 
£20 000 per QALY were close to 0% at six months and approximately 50% at one year, with 
this probability potentially increasing for the extrapolation to two years.
Discussion
The evidence for cost-effectiveness at 12 months was inconclusive. Decompression 
could be cost-effective in the longer-term, but results of this analysis are sensitive to the 
assumptions made about how costs and QALYs are extrapolated beyond the follow-up of 
the trial. 
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decompression with arthroscopy only. Arthroscopy only has 
never been suggested as a routine curative treatment for sub-
acromial pain.
The patients were followed-up for 12 months after randomi-
zation, with the primary endpoint of clinical effectiveness being 
assessed at six months. Full details of the study are reported else-
where,1 and the patient-reported outcome measures (PROMs) 
and clinical results have been published.2 The primary analysis 
used the patients as they were randomized, regardless of com-
pliance using the intention to treat (ITT) principle, and failed to 
show a clinically or statistically significant difference between 
the decompression and arthroscopy only arms, as measured by 
the Oxford Shoulder Score (OSS),6 which was the primary out-
come measure of this RCT. The clinically meaningful difference 
was defined as 4.5 points, and the mean difference for decom-
pression versus arthroscopy only was -1.3 (95% CI -3.9 to 1.3). 
A small statistically, but not clinically, significant improve-
ment was found for both surgical groups compared with the no 
treatment group, with differences still evident at the one-year 
follow-up. A recent study from Finland7 had a similar design but 
included exercise therapy instead of a no treatment arm. Their 
primary endpoint was pain in the shoulder measured on a visual 
analogue scale at 24 months, and the results were consistent 
with the CSAW trial, in that no benefit of decompression over 
arthroscopy was found. No cost-effectiveness analysis has been 
reported for this trial.
The aim of this further study was to compare health-related 
quality of life (QoL), the use of resources, and costs associ-
ated with decompression, arthroscopy only, and no treatment 
for the 313 patients in the CSAW trial. To our knowledge, this 
is the first trial to assess the cost-effectiveness of subacromial 
decompression compared with arthroscopy only and with no 
treatment.
Patients and Methods
The CSAW trial randomized patients from 30 centres in the 
United Kingdom between 2012 and 2015, allocating them to 
one of three options for the management of subacromial pain: 
subacromial decompression, arthroscopy only, and no treat-
ment. Randomization was minimized by site, age (< 40, 40 
to 55, 56+ years), gender, and baseline OSS (< 19, 19 to 26, 
27 to 33, 34+ points). The target sample size was 300 patients 
(100 per arm), based on the primary clinical endpoint, the OSS. 
Inclusion criteria involved subacromial pain for at least three 
months, no evidence of rotator cuff tears, patients who had 
completed a nonoperative management programme, had at least 
one steroid injection, and were eligible for surgery. Additional 
details on the inclusion and exclusion criteria and sample size 
calculation can be found in the protocol.1
The primary outcome of the health economics analysis was 
the incremental cost per quality-adjusted life-year (QALY) 
gained, based on EuroQol (EQ)-5D-3L responses during the 
12-month follow-up. QALYs combine information about QoL 
and time. One QALY signifies one year of life in perfect health, 
and lower values indicate a lower QoL and/or death during that 
year. We focused on decompression versus no treatment and 
decompression versus arthroscopy only. The arthroscopy ver-
sus no treatment comparison is reported for completeness as 
Supplementary Material, but is omitted from the main analysis, 
as arthroscopy was offered only in the context of a randomized 
experiment to control for any surgical placebo effect. Further-
more, it is not considered a valid routine form of treatment for 
these patients. The analysis was undertaken in the United King-
dom’s National Health Service (NHS) healthcare system. The 
time horizon was the duration of the CSAW trial, thus to one 
year after randomization, with data collection at six months and 
one year, with additional longer-term extrapolation of data to 
two years post-randomization.
Data collection and attribution of costs. The costs of the ini-
tial surgical procedures were calculated as a sum of equipment 
costs, which were obtained from manufacturer’s list prices, 
using a 15% discount, costs per minute for the time each patient 
spent in the operating theatre, and a minimal surgical proce-
dure cost for shoulder procedures (day cases), intended to cover 
other items related to a surgical admission such as administra-
tive processing, work-up, and recovery. The small number of 
subsequent operations (two) and adverse events (nine) were not 
costed separately, but treated as included in the resources which 
were used during follow-up. Unit costs for the use of resources 
for the year 2015/16 were obtained from national unit costs 
(Supplementary Table i) and applied to all components.
The following details on the use of resources were collected 
for each patient: the type of initial procedure (decompression, 
arthroscopy only, rotator cuff repair (RCR), and ‘other’, includ-
ing a mixture of intermediate and major procedures) was col-
lected from the theatre form for all patients who underwent a 
surgical procedure within the trial, and the total time in the oper-
ating theatre for each patient. Details of the main equipment 
required for each procedure were identified in discussion with 
the trial team. The use of resources during follow-up, including 
the number of GP and nurse visits, attendance to A&E depart-
ments, orthopaedic and other outpatient clinics and day hospi-
tals, NHS physiotherapy appointments, and overnight inpatient 
stays, were collected at six and 12 months after randomization.
Health-related QoL was measured at baseline, and at six 
and 12 months after randomization using the EQ-5D-3L. Util-
ity scores were calculated from responses using Stata’s ‘eq5d’ 
command,8 using the United Kingdom population tariff;9 index 
scores of 1 indicate full health, 0 represents states equal to 
death, and negative values indicate states considered worse 
than death. QALYs for each patient were calculated using an 
area under the curve (AUC) approach after linear interpolation 
between timepoints.
Cost-effectiveness analyses. All analyses were conducted in 
Stata/SE 14 (StataCorp. LP, College Station, Texas). In the pri-
mary analysis, outcomes were analyzed as randomized, regard-
less of compliance with the randomized procedure (intention to 
treat (ITT) approach). Imputation of missing data allowed for 
the inclusion of all randomized patients. Supplementary analy-
ses included a per-protocol analysis, restricted to those who had 
received only their allocated intervention at 12 months, a com-
plete cases analysis (including only those who had no missing 
observations for any utility or health resource use), and sensi-
tivity analyses for unit costs.
Descriptive statistics (mean and standard errors (se)) for the 
use of resources and related costs were calculated by treatment 
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arm. Differences between treatment arms were adjusted for the 
minimization factors, i.e. linear regression models were adjusted 
for gender, age, and baseline OSS (used as continuous varia-
bles), while also adjusting for clustering within trial site using the 
‘cluster’ option within Stata’s regression command. Differences 
in health-related QoL and QALYs were adjusted for baseline 
EQ-5D-3L values instead of OSS baseline values. 95% confidence 
intervals (CIs) and 5% significance levels were used throughout.
A cost-utility analysis was performed for three different time 
horizons. An analysis covering the six months following ran-
domization was conducted to align with the primary analysis 
of the trial.2 A one-year analysis covered the entire follow-up 
period, and an analysis to 24 months after randomization was 
undertaken to explore cost-effectiveness using some minimal 
assumptions concerning longer-term effects beyond the period 
of follow-up. Incremental cost-effectiveness ratios (ICERs) 
were calculated as the incremental cost per QALY gained for 
each treatment comparison. Uncertainty around the ICERs was 
represented by 1000 non-parametric bootstrapped replicates 
of the differences in mean total cost and QALY between the 
groups, which were then used to plot cost-effectiveness planes 
and to calculate the probability of one treatment arm being 
cost-effective at £20 000 per QALY against its comparator.
The following assumptions were made for the extrapolation 
to two years after randomization: differences in QoL between 
the treatment arms were assumed to remain constant after 12 
months, while no differences were assumed in mean costs 
between different treatment arms after the one-year  follow-up 
point. Further analyses considered a scenario in which costs 
incurred over the six- to 12-month period continued to be 
incurred at the same rate during the following year by each 
patient. Both cost and QoL outcomes beyond one year of 
 follow-up were discounted at an annual rate of 3.5%, in line 
with current recommendations.10
Analyses of sensitivity examined the effect of different dis-
counts in price being applied to the manufacturers’ list prices 
(i.e. 0% and 30% instead of 15%).
Missing data were handled as follows: where patients had 
partly completed information about the use of resources, but had 
left some items unanswered, it was assumed that these health 
care resources were not used within the relevant  follow-up 
period. Where patients had not answered any questions about the 
use of resources or given any EQ-5D-3L data, or the follow-up 
form was missing, multiple imputation by chained equations 
(MICE) was used.11 Missing data for health-related QoL and 
use of resources at baseline (EQ-5D-3L only), six months, and 
12 months after randomization were imputed simultaneously 
using linear regression models and a predicted mean match-
ing approach, imputing observed values from the pool of the 
five data points with the most similar predictive values.11 Addi-
tional independent variables included in the imputation model 
included baseline OSS and EQ-5D-3L index, baseline use of 
Table I. Overview of the randomized patients, initial procedures, and the numbers included in the analyses
Randomized arm
Decompression, 
n (%)
Arthroscopy only, 
n (%)
No treatment, 
n (%)
Total number randomized 106 103 104
Initial procedures
Decompression 80 (75)* 3 (3)† 18 (17)
Arthroscopy only 0 (0) 69 (67)*† 0 (0)
Rotator cuff repairs‡ 5 (5) 4 (4) 1 (1)
Other shoulder surgery 4 (4) 4 (4) 6 (6)
No surgery 17 (16) 23 (22) 79 (76)*§
Populations analyzed
Included in the intention-to-treat population¶ 106 (100) 103 (100) 104 (100)
Included in per-protocol population** 80 (75) 68 (66)† 78 (75)§
Included in complete cases analysis†† 81 (76) 86 (83) 79 (76)
*Patients who received their randomized procedures
†There are two differences between this information and the details provided in the Can Shoulder Arthroscopy Work? 
(CSAW) Consolidated Standards of Reporting Trials (CONSORT) flow diagram shown in the main clinical paper. One 
participant allocated to ‘arthroscopy only’ was listed as having received ‘decompression’ in the main clinical paper at 12 
months. However, the decompression was their second operation; arthroscopy only was initially performed as catego-
rized here. This participant is not included in the per-protocol population
‡Most rotator cuff repairs included decompression
§One participant allocated to the ‘no treatment’ group was listed as withdrawn in the main clinical paper. They did not 
have surgery until the point of withdrawal and they are listed as ‘no surgery’ in this summary for ease of presentation. 
They are not included in the per-protocol population
¶All randomized participants were included in the intention-to-treat population. Missing data were imputed
**The per-protocol population includes all participants who received their allocation intervention, and none of the  
other trial interventions by 12 months post-randomization. Numbers included in this per-protocol population  
differ from those in the main clinical paper, as this analysis does not exclude additional participants due to missing 
outcome data. Missing data were imputed
††The complete cases analysis includes all participants who had no missing observations for any utility or health  
resource use over the 12 months’ follow-up. The numbers included in this complete case analysis are different from 
those in the main clinical paper, which focused on participants with available Oxford Shoulder Score data
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resources, gender, age at randomization, and the initial surgery 
that was undertaken. Imputations were run separately by treat-
ment arm. A total of 20 sets of imputed values were obtained 
using Stata’s ‘mi impute’ command, and combined with the 
‘mi estimate’ command to account for uncertainty around the 
imputations. Information about employment and change in 
employment during the study, the number of sick days, and 
out-of-pocket expenses were summarized descriptively and are 
reported in the Supplementary Material.
Results
A total of 313 patients were randomized, 106 allocated to 
decompression, 103 to arthroscopy only, and 104 to no treat-
ment. The baseline characteristics of the groups were well bal-
anced. The mean age of the patients at the time of entering the 
trial was 53.3 years (sd 10.3), 158 were female (50.5%), and the 
mean OSS was 25.8 (sd 8.5).
The randomized intervention was received by 75%, 67%, and 
76% of patients in the decompression, arthroscopy only, and no 
treatment arms, respectively. Additional details about the initial 
procedures received in each treatment arm (used to generate 
average total surgery costs) and the numbers included in the per- 
protocol and complete cases analyses are shown in Table I.
The rates of returns of the questionnaire were high: 100% 
of baseline questionnaires, 88% at six months, and 85% at 12 
months were received. For a small number of additional patients 
(up to 4% overall), information on the use of resources and 
EQ-5D-3L was missing completely. The type of procedure was 
available for all patients who underwent surgery within the period 
of follow-up. Total times in the operating theatre were missing 
for three patients (one randomized to decompression, two to no 
treatment), who all underwent a decompression. The mean time 
recorded for decompression was used for these patients.
Costs and resource use for the initial trial procedures and 
follow-up. The volume and cost of resources for the initial pro-
cedures and during follow-up are summarized in Table II, with 
full details in Supplementary Table ii.
The mean time in the operating theatre per patient, and hence 
costs for this time, and basic costs of the procedure differed 
significantly between all three treatment arms. The total mean 
costs of surgery per patient were highest in the decompression 
arm (£1767, se 83), followed by the arthroscopy only arm 
(£1299, se 81), and lowest in the no treatment arm (£536, se 95). 
These differences were statistically significant.
During the follow-up from baseline to six months, differ-
ences in the use of resources and costs between treatment arms 
were seen for NHS physiotherapy appointments, day hospital 
admissions, and inpatient nights. Costs for health services use 
during this time, including the cost of the initial procedure, 
were: decompression (£2571, se 113), arthroscopy only (£2287, 
se 144), and no treatment (£1008, se 120). Costs in the decom-
pression arm were significantly higher than for no treatment 
(p < 0.001), but no significant differences were seen between 
the decompression and arthroscopy only arms (p = 0.184).
The use of health services and costs between six and 12 
months’ follow-up were similar across treatment arms. The 
combined costs of surgery and health service use during the fol-
low-up to 12 months were £3147 (se 166) in the decompression 
arm, £2830 (se 183) in the arthroscopy only arm, and £1451 (se 
151) in the no treatment arm. Decompression had significantly 
higher costs than no treatment (p < 0.001); costs in the decom-
pression arm were not significantly different from those in the 
arthroscopy only arm (p = 0.183).
Quality of life outcomes. Information on QoL is presented in 
Table III. Improvements from baseline to six months and 12 
months were seen in all groups. Adjusted mean differences 
between the decompression and no treatment group were sta-
tistically significant at six months (p = 0.007). There were no 
statistically significant differences between decompression and 
arthroscopy only at six or 12 months (six months, p = 0.954; 12 
months, p = 0.397).
Information about the QALYs are shown in Table III. The 
adjusted difference in QALYs during one year follow-up 
between the decompression and arthroscopy only arms was 
not significant. The mean QALYs in the no treatment arm over 
the 12-month follow-up was significantly lower compared 
with the decompression arm (p = 0.002). The QALYs from 
baseline to six months, six to 12 months, and baseline to two 
years were also significantly higher in the decompression arm 
compared with the no treatment arm, but no significant differ-
ences were found between the decompression and arthroscopy 
only arms.
Table II. Overview of the use of resources and costs by randomization allocation 
Decompression, 
mean cost in  
£ (se), n = 106
Arthroscopy only, 
mean cost in  
£ (se), n = 103
No treatment, 
mean cost in  
£ (se), n = 104
Decompression vs  
arthroscopy only, mean  
cost difference in  
£* (95% CI; p-value)
Decompression vs  
no treatment, mean cost  
difference in £* (95% CI;  
p-value)
Total surgery cost 1767 (83) 1299 (81) 536 (95) 461 (274 to 649; < 0.001)† 1231 (955 to 1508; < 0.001)†
Costs of health service use from  
baseline to 6 mths (including initial  
trial procedure where relevant)
2571 (113) 2287 (144) 1008 (120) 266 (-135 to 666; 0.184) 1563 (1169 to 1956; < 0.001)†
Costs of health service use from  
6 to 12 mths
577 (130) 543 (84) 443 (58) 15 (-256 to 286; 0.911) 129 (-148 to 406; 0.346)
Costs of health service use  
and surgery from baseline to 12 mths
3147 (166) 2830 (183) 1451 (151) 281 (-142 to 703; 0.183) 1691 (1216 to 2167; < 0.001)†
*Differences are adjusted for baseline Oxford Shoulder Score, age at randomization, gender, and randomizing site (i.e. adjusted for clustering within 
trial site using the ‘cluster’ option within Stata’s regression command
†Statistically significant
se, standard error; CI, confidence interval
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Table III. Quality of life (QoL) and quality-adjusted life-years (QALYs)
Decompression,  
mean (se), n = 106
Arthroscopy  
only, mean (se),  
n = 103
No treatment, 
mean (se),  
n = 104
Decompression vs  
arthroscopy only,* mean  
(95% CI; p-value)
Decompression vs  
no treatment,* mean  
(95% CI; p-value)
QoL (EQ-5D-3L)
Baseline 0.517 (0.029) 0.553 (0.028) 0.499 (0.032)
6 mths 0.654 (0.030) 0.672 (0.027) 0.526 (0.036) -0.002 (-0.086 to 0.081; p = 0.954) 0.120 (0.040 to 0.210; p = 0.007)†
12 mths 0.735 (0.030) 0.728 (0.027) 0.658 (0.034) 0.027 (-0.038 to 0.093; p = 0.397) 0.080 (-0.010 to 0.160; p = 0.065)
QALYs
Baseline to 6 mths 0.293 (0.012) 0.306 (0.011) 0.256 (0.015) -0.001 (-0.022 to 0.020; p = 0.954) 0.030 (0.010 to 0.050; p = 0.007)†
6 to 12 mths 0.347 (0.013) 0.350 (0.011) 0.296 (0.015) 0.006 (-0.025 to 0.038; p = 0.683) 0.050 (0.020 to 0.080; p = 0.003)†
Baseline to 12 mths 0.640 (0.024) 0.656 (0.020) 0.552 (0.029) 0.006 (-0.045 to 0.056; p = 0.819) 0.080 (0.030 to 0.130; p = 0.002)†
Baseline to 2 yrs‡ 1.349 (0.050) 1.359 (0.043) 1.188 (0.056) 0.032 (-0.072 to 0.136; p = 0.528) 0.160 (0.040 to 0.270; p = 0.008)†
*Differences are adjusted for baseline EQ-5D-3L index, age at randomization, gender, and randomizing site (i.e. adjusted for clustering within trial 
site using the ‘cluster’ option within Stata’s regression command)
†Statistically significant 
‡Assumptions made in the extrapolation: Carry forward quality of life from 12 months; also carry over cost observed from six to 12 months for each 
additional six-month period (extrapolation scenario 1)
se, standard error; EQ-5D-3L, Euro-Qol 5D-3L; CI, confidence interval
Table IV. Incremental cost-effectiveness
Analysis and  
comparison
Difference in costs (£),*  
mean (95% CI; p-value)
Difference in QALYs,*  
mean (95% CI; p-value)
Mean incremental 
cost per QALY  
gained
More  
effective, 
%
Less  
costly, 
%
Cost-effective  
at £20 000 per  
QALY gained, %
Baseline to  
6 mths
Decompression vs 
no treatment
1563  
(1169 to 1956; < 0.001)
0.030  
(0.010 to 0.050; 0.007)
52 100  
(NE quadrant)
100 0 0
Decompression vs 
arthroscopy only
266  
(-135 to 666; 0.184)
-0.001  
(-0.022 to 0.020; 0.954)
-266 000  
(NW quadrant)
53 16 23
Baseline to  
12 mths
Decompression vs 
no treatment
1691  
(1216 to 2167; < 0.001)
0.080  
(0.030 to 0.130; 0.002)
21 138  
(NE quadrant)
100 0 50
Decompression vs 
arthroscopy only
281  
(-142 to 703; 0.183)
0.006  
(-0.045 to 0.056; 0.819)
46 833  
(NE quadrant)
63 17 46
Baseline to 2  
yrs (extrapolation 
scenario 1)†
Decompression vs 
no treatment
1691  
(1216 to 2167; < 0.001)
0.160  
(0.040 to 0.270; 0.008)
10 569  
(NE quadrant)
100 0 89
Decompression vs 
arthroscopy only
281  
(-142 to 703; 0.183)
0.032  
(-0.072 to 0.136; 0.528)
8 781  
(NE quadrant)
76 17 70
Baseline to 2  
yrs (extrapolation 
scenario 2)‡
Decompression vs 
no treatment
1940  
(1046 to 2834; < 0.001)
0.160  
(0.040 to 0.270; 0.008)
12 125  
(NE quadrant)
100 0 84
Decompression vs 
arthroscopy only
309  
(-484 to 1103; 0.428)
0.032  
(-0.072 to 0.136; 0.528)
9656  
(NE quadrant)
76 24 67
*Differences are adjusted for baseline Oxford Shoulder Score (costs)/baseline EQ-5D-3L index, age at randomization, gender, and randomizing site 
(i.e. adjusted for clustering within trial site using the ‘cluster’ option within Stata’s regression command)
†Extrapolation scenario 1: carry forward quality of life from 12 months; assume no differential costs between the treatment arms 
‡Extrapolation scenario 2: carry forward quality of life from 12 months; also carry over cost observed from six to 12 months for each  
additional six-month period
CI, confidence interval; QALY, quality-adjusted life year; NE, north-east quadrant of the cost-effectiveness plane; NW, north-west quadrant of the 
cost-effectiveness plane
Incremental cost-effectiveness. The results from the incre-
mental cost-effectiveness are shown in Table IV (Supplementary 
Table iv also shows the cost-effectiveness for the arthroscopy 
only arm). Significantly larger mean costs were associated 
with the decompression arm compared with the no treatment 
group, while differences in QALYs are small at the six-month 
follow-up and moderate at 12 months. A cost-effectiveness 
plane (Fig. 1, also Supplementary Fig. a) shows the uncertainty 
around the estimates at 12 months. On the cost-effectiveness 
plane, higher values on the vertical axis indicate higher 
differences in cost and points further to the right on the 
horizontal axis indicate a larger difference in QALYs for 
decompression compared with its comparators. Points that fall 
below the dashed line are cost-effective at a £20 000 per QALY 
willingness-to-pay threshold. The probability of decompression 
being cost-effective at a £20 000 per QALY compared with no 
treatment is close to 0% at six months and 50% at 12 months. 
Extrapolating to two years after randomization, the probability 
of decompression being cost-effective compared with no treat-
ment at £20 000 per QALY increases to between 84% and 89% 
for decompression, depending on the assumptions made in the 
extrapolation.
Decompression had similar QoL outcomes to arthros-
copy only at six months, but slightly higher outcomes at 12 
months (adjusted differences), while being a mean of £266 and 
£281 more expensive at six and 12 months, respectively. The 
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probability of decompression being cost-effective compared 
with arthroscopy only at £20 000 per QALY at six and 12 months 
was 23% and 46%, respectively. At two years post randomiza-
tion, the probability of decompression being cost-effective at 
£20 000 compared with arthroscopy only is between 67% and 
70%, depending on the assumptions made in the extrapolation.
The results from the per-protocol analysis, the complete cases 
analyses, and scenarios considering 0% and 30% price discounts 
are consistent with these findings with little evidence of cost- 
effectiveness at a £20 000 per QALY gain threshold (Supple-
mentary Tables v and vi). The probability of decompression 
being cost-effective at £20 000 per QALY compared with no 
treatment or arthroscopy only using the per-protocol population 
is 0% and 8%, respectively, at six months after randomization, 
and 12% and 49%, respectively, at 12 months after randomiza-
tion. By excluding patients who did not receive their allocated 
procedure in the per-protocol analysis, the differences in mean 
costs are more pronounced between the decompression and no 
treatment arms. The changes in these differences are driven by 
the costs of the procedures. Using the complete cases analysis, 
the probability of decompression being cost-effective at £20 000 
per QALY compared with no treatment or arthroscopy only is 
0% and 7%, respectively, at six months after randomization, and 
44% and 31%, respectively, at 12 months after randomization.
Sensitivity analyses examining the effect of other discounts 
applied to surgical equipment (0% and 30% instead of a 15% 
discount as used in the primary analysis) had little effect on 
the differences in cost between treatment arms, as well as the 
ICERs generated, and produced similar results to the primary 
analysis. The effects of the change in discounts were diluted 
by non-compliance to the randomized intervention. Thus, the 
mean cost per patient changed by approximately £80, £44, and 
£23 in the decompression, arthroscopy only, and no treatment 
arms at 12 months, respectively, with increases of this amount 
seen for a decrease in discount to 0%, and a decrease of this 
amount observed for an increase in discount to 30%. These dif-
ferences were small compared with the overall costs per patient 
in each treatment arm, and thus decompression remained sig-
nificantly more expensive than no treatment. The difference in 
costs between decompression and arthroscopy only remained 
non-significant. The probability of decompression being cost- 
effective compared with no treatment at one year remained 
similar to that reported for the primary analysis.
Employment and out-of-pocket expenses. There was no 
evidence of significant differences in employment, change in 
employment, number of sick days (Supplementary Tables vii, 
viii, and ix), use of additional over-the-counter medication, pri-
vate practitioners, and exercise equipment or activities (Sup-
plementary Table x), or costs incurred by the patient, including 
money spent on additional over the counter medication, private 
practitioners and exercise equipment or activities (Supplemen-
tary Table xi) between the treatment arms.
Discussion
We found that randomization to decompression was associated 
with significantly higher costs during a one-year follow-up than 
Cost-effectiveness planes, baseline to 12 months, for a) decompression versus no treatment and b) decompression 
versus arthroscopy only. Points that fall below the dashed line are cost-effective at a £20 000 per quality-adjusted 
life-year (QALY) willingness-to-pay threshold.
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randomization to no treatment (mean difference £1691, 95% CI 
£1216 to £2167). These differences were mainly due to the oper-
ation, and to a lesser extent to an increased health service use, 
particularly the use of physiotherapists, admissions to day hospi-
tals, and inpatient nights during the first six months of follow-up. 
We found no significant differences in costs between the decom-
pression and arthroscopy arms during the 12 months’ follow- 
up. At six months after randomization, self-reported QoL was 
significantly higher in both surgery arms compared with no 
treatment, but not significantly different between those rand-
omized to decompression and arthroscopy only. There were no 
significant differences in QoL at the end of the 12-month follow- 
up period, although those in the decompression arm had a mar-
ginally higher mean EQ-5D-3L value than those in the arthros-
copy only arm. Similar trends were observed for other PROMs 
recorded in the CSAW trial.2
For both decompression versus no treatment and decompres-
sion versus arthroscopy only, there is an approximately 50% 
chance of being cost-effective at £20 000 per QALY gained at 
the end of the one-year follow-up. Extrapolating the outcomes 
to two years after randomization, in particular assuming that 
small differences in QoL at 12 months persist to 24 months, 
had a large effect on the results, increasing the probability of 
decompression versus no treatment and decompression versus 
arthroscopy only being cost-effective. However, no long-term 
data are available on these patients, and it is not known how 
realistic these assumptions are.
This cost-effectiveness analysis was conducted alongside 
a RCT that recruited patients from 30 hospitals in the United 
Kingdom, and so is broadly based and had low levels of loss to 
follow-up and missing data. However, it has limitations. First, 
information on actual discounts offered to hospitals for surgical 
equipment is hard to obtain, and so the same level of discount 
was assumed across all sites. However, analyses of sensitivity 
examining different levels of discounts did not greatly alter the 
results. Second, not all patients received their randomized pro-
cedure. Between 24% and 33% of patients were treated with 
other or additional procedures. The costs therefore incorporate 
a mixture of procedures and the results should be interpreted as 
an ITT analysis. Third, the analysis was performed from the per-
spective of the healthcare system alone, and information about 
wider societal costs such as time off work, and out-of-pocket 
expenses that were incurred by patients was only summarized 
descriptively, and is reported as Supplementary Material. 
Finally, the maximum duration of follow-up was 12 months, 
which may not have been long enough to capture longer-term 
effects of the procedures with respect to costs and particularly 
QoL. A simple extrapolation over a short period of an additional 
12 months and using highly restrictive assumptions neverthe-
less had a large effect on the estimates of cost-effectiveness.
In the CSAW trial, arthroscopy only was offered as part of 
the randomized experiment to control for any surgical pla-
cebo effect. The results from a cost-effectiveness analysis of 
a comparison between arthroscopy only versus no treatment 
are not easily interpretable, since, even if shown to be cost- 
effective, the arthroscopy only procedure could not be used in 
these patients. We have not discussed these results in this paper, 
although they are shown in the Supplementary Material.
In conclusion, this study shows no evidence that decompres-
sion is cost-effective during the one-year follow-up period. It 
could be cost-effective in the long-term, but results of this 
analysis are sensitive to the assumptions made about how costs 
and QALYs are extrapolated beyond the follow-up of the trial. 
Studies with longer-term follow-up are needed.
Take home message
- Arthroscopic subacromial decompression is a commonly 
performed surgery in patients with subacromial pain, but re-
cent research demonstrated no clinical benefit of decompres-
sion surgery compared with arthroscopy only or no treatment.
- This study is the first to assess the cost-effectiveness of subacromial 
decompression compared to arthroscopy only and to no treatment.
- This research adds comparative evidence on the costs and quality of life 
of these procedures. It shows that decompression is significantly more 
costly than no treatment over 12 months, with no clear evidence that it 
is cost-effective.
- Further evidence on longer-term outcomes and costs is still required, 
as in some projected scenarios decompression could be cost-effective 
depending on how costs and QALYs are extrapolated beyond the trial 
follow-up.
Twitter
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Supplementary material (available online)
Tables and figures showing unit costs, as well as 
 detailed information on resource use, costs, and qual-
ity of life, are provided in the Supplementary Material. 
Incremental cost-effectiveness for the sensitivity analyses at six 
months and 12 months post-randomization (per-protocol and 
complete case analysis, variation in price discounts), as well as 
adjusted differences between the arthroscopy only and no treat-
ment arm, are also presented. Cost-effectiveness planes for all 
comparisons covering time from randomization to 12 months 
and for the extrapolation to 24 months are included. Tables 
summarizing employment and change of employment informa-
tion, sick days, use of additional over-the-counter medication, 
use of private practitioners, and money spent on exercise equip-
ment or activities are presented.
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